Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), ... present a company overview at the Nomura Biotechnology Conference on ... Boston, MA. A live webcast ... Media" section of the Company,s website, www.isispharm.com .  A ... hours and will be archived for a limited time. ...
(Date:10/30/2014)... 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... conference call and live audio webcast on Thursday, November ... third quarter 2014 financial results. Interested participants ... (888) 347-1165 for domestic callers or (412) 902-4276 for ... under the investor relations section of the Regado website ...
(Date:10/30/2014)... flooding that devastated a wide swath of Colorado last ... roads and other infrastructure had been upgraded or modernized, ... Colorado Denver. , "People need to understand the importance ... professor of structural engineering at the CU Denver College ... study. "There is an assumption that a bridge will ...
(Date:10/27/2014)... The new research report, “Gas Insulated Switchgear ... (Primary & Secondary), and End-User (Transmission & Distribution, ... Generation) - Trends and Forecasts to 2019”, defines ... forecasting of the market size. , Browse more ... spread through 146 Pages and in-depth TOC on ...
Breaking Biology Technology:Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... Inc.,announced today that it has been awarded a ... Research (SBIR) grant, entitled,"Long-Acting Beta Interferon for Multiple ... Stroke (NINDS) of The National,Institutes of Health (NIH). ... the achievement of certain research milestones., George ...
... scientific and business development flexibility, TSX Exchange ... Resverlogix Corp.,("Resverlogix") (TSX:RVX) announced today that it has ... USD$17.3 million debenture., Donald McCaffrey, President and ... volatile and challenging for companies,around the globe. This ...
... begin after markets close at 2:00 p.m. PT ... ... MASI ), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion- and-Low-Perfusion pulse oximetry, today ... 2008 after the market closes on Monday, October 27, 2008., A ...
Cached Biology Technology:Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug 2Resverlogix Eliminates Sixty Percent of Remaining Debt 2Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2
(Date:10/30/2014)... 29, 2014  Securus Technologies, a leading ... solutions for public safety, investigation, corrections and ... exciting enhancements to its THREADS™ product, which ... actionable intelligence and focused leads for investigators. ... technological innovation through identifying and delivering solutions ...
(Date:10/29/2014)... 2014, Beaverton, OR) New research presented at ... Conference in Houston, TX showed for the first ... infection in women using a readily available nutritional ... presented by Dr. Judith A. Smith, Pharm.D., associate ... Reproductive Sciences at The University of Texas Health ...
(Date:10/29/2014)... An overwhelming number of chemicals from household and industrial ... in our bodies. But for most of them, scientists ... Now they,ve taken the first step toward doing that ... most. Their new method is published in the ACS ... F. Wambaugh and colleagues note that the risks to ...
Breaking Biology News(10 mins):Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
... of New South Wales have cautioned that more ... to the disinfecting properties of silver nano-particles, increasingly ... nanosilver has effective antimicrobial properties against certain pathogens, ... harmful organisms to rapidly adapt and flourish, a ...
... 8 May 2013 (Geneva, Switzerland) - Strategies for pursuing ... at higher CD4 counts and innovative models for HIV ... programme announced today. , "Functional cures" and the benefits ... this year and the IAS 20I3 conference, the worlds ...
... York City,s Central Park to Golden Gate Park in San ... of carbon, an environmental service with an estimated value of ... Annual net carbon uptake by these trees is ... benefit. In the study published recently in the journal ...
Cached Biology News:Bacteria adapt and evade nanosilver's sting -- new study 2IAS 2013 conference program live online 2IAS 2013 conference program live online 3US urban trees store carbon, provide billions in economic value 2US urban trees store carbon, provide billions in economic value 3US urban trees store carbon, provide billions in economic value 4US urban trees store carbon, provide billions in economic value 5US urban trees store carbon, provide billions in economic value 6
... Arrays can be used to test the ... and sera that are commonly used as ... contains spots for 21 different protein preparations ... antibody crossreactivity and species specificity, QC of ...
... the experimental process of determining the nucleotide ... DNA Sequencing is based on Sangers enzymatic ... allows cycle sequencing reactions. The resulting fluorescent ... capillary instrument controlled by a computer and ...
... On-Demand Cytometry The Guava EasyCyte ... laser based multiparameter cytometer with built-in 96-well ... can screen plates of cells and compounds ... manipulating multiple tubes or having the carryover ...
... and finishing services are tailored to ... large-scale 5' screening or full length ... experience with large-scale genome projects and ... ideal cDNA outsourcing solution. In addition, ...
Biology Products: